Lactobacillus acidophilus 用于 肠易激综合征（IBS）
B 证据 至少一项随机试验支持这一结论，结果基本一致。改善肠道传输时间，减轻IBS-C的便秘症状。粪便pH下降提示发酵改善。对嗜酸乳杆菌NCFM菌株的证据最佳。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dacidophilus\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
结论
改善肠道传输时间，减轻IBS-C的便秘症状。粪便pH下降提示发酵改善。对嗜酸乳杆菌NCFM菌株的证据最佳。
Key Study Findings
Randomized Controlled Trial
n=200
12 weeks
Double-blind
Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable …
Dose: None
vs: placebo
Outcome: IBS-Global Improvement Scale response
效果: 19.3% vs 8.9% response at day 28
p=0.048
研究人群: adults with non-constipated irritable bowel syndrome
Meta-Analysis
n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None
vs: placebo
Outcome: quality of life, depression, and anxiety in IBS …
效果: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression)
None
研究人群: patients with irritable bowel syndrome
Randomized Controlled Trial
n=61
12 weeks
Double-blind
Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel …
Dose: None
vs: Placebo
Outcome: IBS-SSS (100-point reduction)
效果: 45% active vs 33% placebo (P=0.42)
P=0.42
研究人群: IBD patients with IBS symptoms in remission
Randomized Controlled Trial
4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g
vs: Placebo
Outcome: Constipation symptoms
效果: None
P = 0.005
研究人群: IBS patients
Randomized Controlled Trial
12 weeks
Double-blind
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides …
Dose: None
vs: Placebo
Outcome: Quality of life
效果: None
p = 0.023
研究人群: IBS patients
Other
Computational prediction of new therapeutic effects of probiotics.
Dose: None
vs: None
Outcome: Colitis severity
效果: None
None
研究人群: Crohn's disease patients
Key Statistics
3
研究数量
350
受试者
↑
Positive
B
等级
Referenced Papers
Journal of gastroenterology …
2026
1 次引用
European journal of …
2026
World journal of …
2025
2 次引用
Scientific reports
2024
20 次引用
Scientific reports
2024
10 次引用
The Yale journal …
2024
5 次引用
Journal of clinical …
2024
4 次引用
Journal of neurogastroenterology …
2024
4 次引用
International journal of …
2024
2 次引用
Nutrients
2023
33 次引用
Anaerobe
2023
14 次引用
International journal of …
2023
9 次引用
Minerva pediatrics
2023
2 次引用
Voprosy pitaniia
2023
Journal of neurogastroenterology …
2022
21 次引用
Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis.
Systematic Review
Nutrients
2022
19 次引用
Gastroenterology research and …
2022
15 次引用
Microorganisms
2021
47 次引用
Acta gastro-enterologica Belgica
2021
14 次引用
Nutrients
2020
99 次引用
Nutrients
2020
78 次引用
Digestive and liver …
2020
28 次引用
Cellular and molecular …
2020
4 次引用
Probiotics and antimicrobial …
2019
43 次引用
Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model.
Other
BMC complementary and …
2019
24 次引用
Diseases (Basel, Switzerland)
2018
50 次引用
Beneficial microbes
2018
48 次引用
Saudi journal of …
2018
41 次引用
Cellular and molecular …
2017
9 次引用
World journal of …
2016
99 次引用
Journal of dairy …
2016
67 次引用
Journal of clinical …
2015
62 次引用
Journal of gastroenterology …
2014
164 次引用
Orvosi hetilap
2014
6 次引用
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 次引用
Scandinavian journal of …
2013
74 次引用
PloS one
2012
445 次引用
Journal of clinical …
2012
207 次引用
Revista de gastroenterologia …
2012
Journal of clinical …
2011
163 次引用
Alimentary pharmacology & …
2010
4 次引用
Neurogastroenterology and motility
2009
81 次引用
Gut and liver
2009
77 次引用
Digestive diseases and …
2008
160 次引用
Current opinion in …
2008
68 次引用
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors.
Other
Nature medicine
2007
774 次引用
Minerva gastroenterologica e …
2006
22 次引用
Journal of clinical …
2004
298 次引用
Journal of clinical …
2004
205 次引用
The American journal …
1983
78 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 1-10 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- lactosesupport:
- 1-2 billion CFU with dairy consumption
上限： Generally well-tolerated up to 20 billion CFU/day
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | 12 weeks | Positive | 200 |
| None | -- | Positive | 3154 |
| None | 12 weeks | Neutral | 61 |
| 2 g | 4 weeks | Mixed | -- |
| None | 12 weeks | Positive | -- |
| None | -- | Neutral | -- |
| 10^9 CFU L. acidophilus LA-5 + L. paracasei daily | 12 weeks | Positive | 110 |
| None | -- | Positive | -- |
最佳服用时间： On an empty stomach or before meals; may also be taken with dairy
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional loose stools
- ⚠ Rare allergic reactions in dairy-sensitive individuals (dairy-cultured strains)
- ⚠ Very rare: bacteremia in immunocompromised individuals
已知相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
- ● Sulfasalazine (may affect bacterial metabolism)
可耐受最高摄入量： Generally well-tolerated up to 20 billion CFU/day
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Lactobacillus acidophilus help with 肠易激综合征（IBS）?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus acidophilus may support 肠易激综合征（IBS） management. Our evidence grade is B (Good Evidence).
How much Lactobacillus acidophilus should I take for 肠易激综合征（IBS）?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus acidophilus?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Rare allergic reactions in dairy-sensitive individuals (dairy-cultured strains), Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus acidophilus and 肠易激综合征（IBS）?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.
Related Evidence
References
- [1] Uday C Ghoshal et al.. J Gastroenterol Hepatol. 2026. Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable Bowel Syndrome: A Double-Blind Randomized … doi:10.1111/jgh.70137 PubMed
- [2] Theodore Rokkas et al.. Eur J Gastroenterol Hepatol. 2026. Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable bowel syndrome: a systematic review … doi:10.1097/MEG.0000000000003062 PubMed
- [3] Anne Fennessy et al.. World J Gastrointest Pharmacol Ther. 2025. Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation … doi:10.4292/wjgpt.v16.i2.101268 PubMed
- [4] Marlynna Sarkawi et al.. Sci Rep. 2024. A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome. doi:10.1038/s41598-024-60029-2 PubMed
- [5] Sadegh Sulaimany et al.. Sci Rep. 2024. Computational prediction of new therapeutic effects of probiotics. doi:10.1038/s41598-024-62796-4 PubMed
- [6] Mattia Tinazzi et al.. Yale J Biol Med. 2024. Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … doi:10.59249/JOMF5336 PubMed
- [7] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [8] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
- [9] Lena Capirchio et al.. Int J Mol Sci. 2024. A Synbiotic Combining Chitin-Glucan and Lactobacillus acidophilus NCFM Induces a Colonic Molecular Signature Soothing Intestinal Pain and Inflammation in an … doi:10.3390/ijms251910732 PubMed
- [10] Peiwei Xie et al.. Nutrients. 2023. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. doi:10.3390/nu15173856 PubMed
- [11] Arzu Hizay et al.. Anaerobe. 2023. Lactobacillus acidophilus regulates abnormal serotonin availability in experimental ulcerative colitis. doi:10.1016/j.anaerobe.2023.102710 PubMed
- [12] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [13] Veronica Cocetta et al.. Minerva Pediatr (Torino). 2023. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. doi:10.23736/S2724-5276.23.07128-8 PubMed
- [14] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [15] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
- [16] Cecilia Ceccherini et al.. Nutrients. 2022. Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis. doi:10.3390/nu14132689 PubMed
- [17] Jin Lee et al.. Gastroenterol Res Pract. 2022. Clinical Efficacy of Probiotic Therapy on Bowel-Related Symptoms in Patients with Ulcerative Colitis during Endoscopic Remission: An Observational Study. doi:10.1155/2022/9872230 PubMed
- [18] Luisa Marras et al.. Microorganisms. 2021. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia. doi:10.3390/microorganisms9040836 PubMed
- [19] N Md Mokhtar et al.. Acta Gastroenterol Belg. 2021. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. doi:10.51821/84.4.009 PubMed
- [20] Christopher J Martoni et al.. Nutrients. 2020. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. doi:10.3390/nu12020363 PubMed
- [21] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [22] Stéphane Sadrin et al.. Dig Liver Dis. 2020. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. doi:10.1016/j.dld.2019.12.009 PubMed
- [23] Jean Michel Maixent et al.. Cell Mol Biol (Noisy-le-grand). 2020. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future … PubMed
- [24] Konstantinos Leventogiannis et al.. Probiotics Antimicrob Proteins. 2019. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. doi:10.1007/s12602-018-9401-3 PubMed
- [25] Ki-Bae Hong et al.. BMC Complement Altern Med. 2019. Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model. doi:10.1186/s12906-019-2610-9 PubMed
- [26] Mary Scriven et al.. Diseases. 2018. Neuropsychiatric Disorders: Influence of Gut Microbe to Brain Signalling. doi:10.3390/diseases6030078 PubMed
- [27] K Preston et al.. Benef Microbes. 2018. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. doi:10.3920/BM2017.0105 PubMed
- [28] Ya-Nan Cao et al.. Saudi J Gastroenterol. 2018. Lactobacillus acidophilus and Bifidobacterium longum supernatants upregulate the serotonin transporter expression in intestinal epithelial cells. doi:10.4103/sjg.SJG_333_17 PubMed
- [29] S Sadrin et al.. Cell Mol Biol (Noisy-le-grand). 2017. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial. doi:10.14715/cmb/2017.63.9.21 PubMed
- [30] Anna Lyra et al.. World J Gastroenterol. 2016. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. doi:10.3748/wjg.v22.i48.10631 PubMed
- [31] Bojana Bogovič Matijašić et al.. J Dairy Sci. 2016. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of … doi:10.3168/jds.2015-10743 PubMed
- [32] Hyuk Yoon et al.. J Clin Biochem Nutr. 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … doi:10.3164/jcbn.15-14 PubMed
- [33] Jun Sik Yoon et al.. J Gastroenterol Hepatol. 2014. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. doi:10.1111/jgh.12322 PubMed
- [34] János Fehér et al.. Orv Hetil. 2014. [Correlation of the microbiota and intestinal mucosa in the pathophysiology and treatment of irritable bowel, irritable eye, and irritable mind … doi:10.1556/OH.2014.29987 PubMed
- [35] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
- [36] Luise Mølenberg Begtrup et al.. Scand J Gastroenterol. 2013. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. doi:10.3109/00365521.2013.825314 PubMed
- [37] Marina L Ritchie et al.. PLoS One. 2012. A meta-analysis of probiotic efficacy for gastrointestinal diseases. doi:10.1371/journal.pone.0034938 PubMed
- [38] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
- [39] Javier Diaz Ferrer et al.. Rev Gastroenterol Peru. 2012. [Probiotic supplement (Lactobacillus acidophilus and bulgaricus) utility in the treatment of irritable bowel syndrome]. PubMed
- [40] Tamar Ringel-Kulka et al.. J Clin Gastroenterol. 2011. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional … doi:10.1097/MCG.0b013e31820ca4d6 PubMed
- [41] A C Ford. Aliment Pharmacol Ther. 2010. Probiotics in irritable bowel syndrome: underachievers or underpowered? doi:10.1111/j.1365-2036.2009.04223.x PubMed
- [42] L Ohman et al.. Neurogastroenterol Motil. 2009. B-cell activation in patients with irritable bowel syndrome (IBS). doi:10.1111/j.1365-2982.2009.01272.x PubMed
- [43] Kyoung Sup Hong et al.. Gut Liver. 2009. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. doi:10.5009/gnl.2009.3.2.101 PubMed
- [44] Dong Hyun Sinn et al.. Dig Dis Sci. 2008. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. doi:10.1007/s10620-007-0196-4 PubMed
- [45] Eamonn M M Quigley. Curr Opin Pharmacol. 2008. Probiotics in functional gastrointestinal disorders: what are the facts? doi:10.1016/j.coph.2008.08.007 PubMed
- [46] Christel Rousseaux et al.. Nat Med. 2007. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. doi:10.1038/nm1521 PubMed
- [47] M Astegiano et al.. Minerva Gastroenterol Dietol. 2006. Treatment of irritable bowel syndrome. A case control experience. PubMed
- [48] Thomas J Borody et al.. J Clin Gastroenterol. 2004. Bacteriotherapy using fecal flora: toying with human motions. doi:10.1097/01.mcg.0000128988.13808.dc PubMed
- [49] Alfredo Saggioro. J Clin Gastroenterol. 2004. Probiotics in the treatment of irritable bowel syndrome. doi:10.1097/01.mcg.0000129271.98814.e2 PubMed
- [50] A D Newcomer et al.. Am J Clin Nutr. 1983. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. doi:10.1093/ajcn/38.2.257 PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。